CJ HealthCare applies new drug approval of acid reflex treatment

Published: 2017-09-06 13:10:40

Updated: 2017-09-06 13:10:40

The CJ HealthCare’s first new medicine, an acid reflux treatment, has taken a approval process in Korea its launch.

CJ HealthCare(CEO Seok-Hee Kang) announced on the 4^th that it applied product approval of ‘tegoprazan(Code name: CJ-12420),’ a new acid reflux treatment, to the Ministry of Food and Drug Safety(MFDS) on the 31^st of August.

The recently applied ‘tegoprazan’ is a new type of gastr...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.